m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01069)
Name
[1,3]Oxazinan-(2E)-ylideneamine
Synonyms
5,6-dihydro-4h-1,3-oxazin-2-amine; CHEMBL161118; 1848-68-6; [1,3]Oxazinan-(2E)-ylideneamine; SCHEMBL31223; 2-iminotetrahydro-1,3-oxazine; MolPort-044-586-586; BDBM50049258; ZINC13746441; AKOS025312622; AKOS006338233; 2-amino-5,6-dihydro-4h-1,3-oxazine
    Click to Show/Hide
Status
Investigative
Structure
Formula
C4H8N2O
InChI
1S/C4H8N2O/c5-4-6-2-1-3-7-4/h1-3H2,(H2,5,6)
InChIKey
VPVZSRIIAONGMU-UHFFFAOYSA-N
PubChem CID
23042899
TTD Drug ID
D0M4BM
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Nitric oxide synthase endothelial (NOS3)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Nitric oxide synthase endothelial (NOS3) is a therapeutic target for [1,3]Oxazinan-(2E)-ylideneamine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of [1,3]Oxazinan-(2E)-ylideneamine through regulating the expression of Nitric oxide synthase endothelial (NOS3). [1], [2]
References
Ref 1 N6-Methyladenosine Demethylase FTO (Fat Mass and Obesity-Associated Protein) as a Novel Mediator of Statin Effects in Human Endothelial Cells. Arterioscler Thromb Vasc Biol. 2022 May;42(5):644-658. doi: 10.1161/ATVBAHA.121.317295. Epub 2022 Mar 17.
Ref 2 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. doi: 10.1021/jm950766n.